A new marker could be useful for diagnosing and treating neuroendocrine tumors of the small intestines.

The glutamine transporter protein appears to contribute to the survival of lung cancer cells, suggesting it may be a useful diagnostic biomarker and target for therapies.

La Jolla Pharmaceutical Co. and Vanderbilt University have signed a research and license agreement covering Vanderbilt’s research program and intellectual property rights related to compounds that block bone morphogenetic protein (BMP) type-I receptors. The compounds have therapeutic potential in a broad range of diseases, including rare genetic disorders.

A new genetic model has generated new strategies for promoting tolerance to transplants – and improving long-term transplant outcomes – in the background of autoimmune disease.

The co-creator of the world’s first microelectronic multi-channel cochlear implant — a device that provides sound signals to the brain in deaf individuals — will deliver the next Flexner Discovery Lecture.

Vanderbilt investigators have defined a gene expression program that controls the timing of synaptic remodeling – a process that is critical to brain development, learning and memory.